menu search

ARCT / Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race

Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race
Arcturus Therapeutics is developing mRNA medicines and vaccines for infectious diseases and rare disorders, with a focus on their ARCT-810 candidate for ornithine transcarbamylase deficiency. The company reported strong Q1 2023 financial results, with a significant increase in revenue and a net income of $50.8 million, along with a cash runway projected to last until early 2026. Despite late entry into the COVID-19 vaccine market, Arcturus' focus on rare diseases and their financial health make them an attractive investment opportunity, with a speculative 'Buy' recommendation. Read More
Posted: Jun 26 2023, 13:40
Author Name: Seeking Alpha
Views: 092057

ARCT News  

Arcturus: Interim Readout Of Rare Disease Data In Coming Months

By Seeking Alpha
September 7, 2023

Arcturus: Interim Readout Of Rare Disease Data In Coming Months

Results from phase 2 study using ARCT-810 for the treatment of patients with Ornithine-Transcarbamylase [OTC] deficiency are expected in the coming mo more_horizontal

Arcturus Therapeutics to Attend Upcoming Investor Conferences

By Business Wire
August 17, 2023

Arcturus Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global l more_horizontal

New Strong Sell Stocks for August 10th

By Zacks Investment Research
August 10, 2023

New Strong Sell Stocks for August 10th

ARCT, AVY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2023. more_horizontal

Why Shares of Arcturus Therapeutics Dropped on Tuesday

By The Motley Fool
August 8, 2023

Why Shares of Arcturus Therapeutics Dropped on Tuesday

Arcturus Therapeutics has several collaboration agreements. The company is a clinical-stage biotech. more_horizontal

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 7, 2023

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.98 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of more_horizontal

3 Biotech Stocks to Buy Before the Breakout

By InvestorPlace
July 28, 2023

3 Biotech Stocks to Buy Before the Breakout

During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirmin more_horizontal

Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?

By Zacks Investment Research
July 17, 2023

Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings esti more_horizontal

Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race

By Seeking Alpha
June 26, 2023

Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race

Arcturus Therapeutics is developing mRNA medicines and vaccines for infectious diseases and rare disorders, with a focus on their ARCT-810 candidate f more_horizontal


Search within

Pages Search Results: